Use and abuse of dissociative and psychedelic drugs in adolescence

Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and prec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2021-04, Vol.203, p.173129-173129, Article 173129
Hauptverfasser: Bates, M.L. Shawn, Trujillo, Keith A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 173129
container_issue
container_start_page 173129
container_title Pharmacology, biochemistry and behavior
container_volume 203
creator Bates, M.L. Shawn
Trujillo, Keith A.
description Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage. •Adolescents use dissociatives, classic psychedelics and MDMA recreationally.•There is evidence of age differences in responses to these drugs in humans and animal models.•Gaps in the understanding of adolescent use of these drugs are identified.•Recommendations are made for future research on the topic.
doi_str_mv 10.1016/j.pbb.2021.173129
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11578551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305721000277</els_id><sourcerecordid>2483815780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-1c30f81a821d5d2408feca6030687a388d79956d5038627d69148eb2f725d63f3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMoun78AC_So5eumaT5KB5ExS8QvOg5pEmqWbrNmrQL_nuzVEUvnmZgnnkneRA6BjwHDPxsMV81zZxgAnMQFEi9hWYgBS0ZCLGNZhjXUFLMxB7aT2mBMa4IF7toj1IGjEk-Q1cvyRW6t4VuxtyFtrA-pWC8Hvx6mqzSh3lz1nXeFDaOr6nwfaFt6FwyrjfuEO20ukvu6KseoJfbm-fr-_Lx6e7h-vKxNBUjQwmG4laClgQss6TCsnVGc0wxl0JTKa2oa8Ytw1RyIiyvoZKuIa0gzHLa0gN0MeWuxmbpbL49RN2pVfRLHT9U0F79nfT-Tb2GtQJgQjIGOeH0KyGG99GlQS19_kPX6d6FMSlSSSo3MM4oTKiJIaXo2p87gNVGvlqoLF9t5KtJft45-f3An41v2xk4nwCXNa29iyoZv1FofXRmUDb4f-I_AZAYlBs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2483815780</pqid></control><display><type>article</type><title>Use and abuse of dissociative and psychedelic drugs in adolescence</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bates, M.L. Shawn ; Trujillo, Keith A.</creator><creatorcontrib>Bates, M.L. Shawn ; Trujillo, Keith A.</creatorcontrib><description>Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage. •Adolescents use dissociatives, classic psychedelics and MDMA recreationally.•There is evidence of age differences in responses to these drugs in humans and animal models.•Gaps in the understanding of adolescent use of these drugs are identified.•Recommendations are made for future research on the topic.</description><identifier>ISSN: 0091-3057</identifier><identifier>ISSN: 1873-5177</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/j.pbb.2021.173129</identifier><identifier>PMID: 33515586</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adolescence ; Adolescent ; Adult ; Age Factors ; Animals ; Dextromethorphan - administration & dosage ; Dissociatives ; Female ; Hallucinogens - administration & dosage ; Humans ; Ketamine - administration & dosage ; Lysergic Acid Diethylamide - administration & dosage ; Male ; MDMA ; N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage ; Phencyclidine - administration & dosage ; Psilocybin - administration & dosage ; Psychedelics ; Reward ; Risk-Taking ; Substance-Related Disorders - epidemiology ; Substance-Related Disorders - psychology]]></subject><ispartof>Pharmacology, biochemistry and behavior, 2021-04, Vol.203, p.173129-173129, Article 173129</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-1c30f81a821d5d2408feca6030687a388d79956d5038627d69148eb2f725d63f3</citedby><cites>FETCH-LOGICAL-c452t-1c30f81a821d5d2408feca6030687a388d79956d5038627d69148eb2f725d63f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pbb.2021.173129$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33515586$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bates, M.L. Shawn</creatorcontrib><creatorcontrib>Trujillo, Keith A.</creatorcontrib><title>Use and abuse of dissociative and psychedelic drugs in adolescence</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage. •Adolescents use dissociatives, classic psychedelics and MDMA recreationally.•There is evidence of age differences in responses to these drugs in humans and animal models.•Gaps in the understanding of adolescent use of these drugs are identified.•Recommendations are made for future research on the topic.</description><subject>Adolescence</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Animals</subject><subject>Dextromethorphan - administration &amp; dosage</subject><subject>Dissociatives</subject><subject>Female</subject><subject>Hallucinogens - administration &amp; dosage</subject><subject>Humans</subject><subject>Ketamine - administration &amp; dosage</subject><subject>Lysergic Acid Diethylamide - administration &amp; dosage</subject><subject>Male</subject><subject>MDMA</subject><subject>N-Methyl-3,4-methylenedioxyamphetamine - administration &amp; dosage</subject><subject>Phencyclidine - administration &amp; dosage</subject><subject>Psilocybin - administration &amp; dosage</subject><subject>Psychedelics</subject><subject>Reward</subject><subject>Risk-Taking</subject><subject>Substance-Related Disorders - epidemiology</subject><subject>Substance-Related Disorders - psychology</subject><issn>0091-3057</issn><issn>1873-5177</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMoun78AC_So5eumaT5KB5ExS8QvOg5pEmqWbrNmrQL_nuzVEUvnmZgnnkneRA6BjwHDPxsMV81zZxgAnMQFEi9hWYgBS0ZCLGNZhjXUFLMxB7aT2mBMa4IF7toj1IGjEk-Q1cvyRW6t4VuxtyFtrA-pWC8Hvx6mqzSh3lz1nXeFDaOr6nwfaFt6FwyrjfuEO20ukvu6KseoJfbm-fr-_Lx6e7h-vKxNBUjQwmG4laClgQss6TCsnVGc0wxl0JTKa2oa8Ytw1RyIiyvoZKuIa0gzHLa0gN0MeWuxmbpbL49RN2pVfRLHT9U0F79nfT-Tb2GtQJgQjIGOeH0KyGG99GlQS19_kPX6d6FMSlSSSo3MM4oTKiJIaXo2p87gNVGvlqoLF9t5KtJft45-f3An41v2xk4nwCXNa29iyoZv1FofXRmUDb4f-I_AZAYlBs</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Bates, M.L. Shawn</creator><creator>Trujillo, Keith A.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210401</creationdate><title>Use and abuse of dissociative and psychedelic drugs in adolescence</title><author>Bates, M.L. Shawn ; Trujillo, Keith A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-1c30f81a821d5d2408feca6030687a388d79956d5038627d69148eb2f725d63f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescence</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Animals</topic><topic>Dextromethorphan - administration &amp; dosage</topic><topic>Dissociatives</topic><topic>Female</topic><topic>Hallucinogens - administration &amp; dosage</topic><topic>Humans</topic><topic>Ketamine - administration &amp; dosage</topic><topic>Lysergic Acid Diethylamide - administration &amp; dosage</topic><topic>Male</topic><topic>MDMA</topic><topic>N-Methyl-3,4-methylenedioxyamphetamine - administration &amp; dosage</topic><topic>Phencyclidine - administration &amp; dosage</topic><topic>Psilocybin - administration &amp; dosage</topic><topic>Psychedelics</topic><topic>Reward</topic><topic>Risk-Taking</topic><topic>Substance-Related Disorders - epidemiology</topic><topic>Substance-Related Disorders - psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bates, M.L. Shawn</creatorcontrib><creatorcontrib>Trujillo, Keith A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bates, M.L. Shawn</au><au>Trujillo, Keith A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use and abuse of dissociative and psychedelic drugs in adolescence</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>203</volume><spage>173129</spage><epage>173129</epage><pages>173129-173129</pages><artnum>173129</artnum><issn>0091-3057</issn><issn>1873-5177</issn><eissn>1873-5177</eissn><abstract>Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage. •Adolescents use dissociatives, classic psychedelics and MDMA recreationally.•There is evidence of age differences in responses to these drugs in humans and animal models.•Gaps in the understanding of adolescent use of these drugs are identified.•Recommendations are made for future research on the topic.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33515586</pmid><doi>10.1016/j.pbb.2021.173129</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0091-3057
ispartof Pharmacology, biochemistry and behavior, 2021-04, Vol.203, p.173129-173129, Article 173129
issn 0091-3057
1873-5177
1873-5177
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11578551
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adolescence
Adolescent
Adult
Age Factors
Animals
Dextromethorphan - administration & dosage
Dissociatives
Female
Hallucinogens - administration & dosage
Humans
Ketamine - administration & dosage
Lysergic Acid Diethylamide - administration & dosage
Male
MDMA
N-Methyl-3,4-methylenedioxyamphetamine - administration & dosage
Phencyclidine - administration & dosage
Psilocybin - administration & dosage
Psychedelics
Reward
Risk-Taking
Substance-Related Disorders - epidemiology
Substance-Related Disorders - psychology
title Use and abuse of dissociative and psychedelic drugs in adolescence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T08%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20and%20abuse%20of%20dissociative%20and%20psychedelic%20drugs%20in%20adolescence&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Bates,%20M.L.%20Shawn&rft.date=2021-04-01&rft.volume=203&rft.spage=173129&rft.epage=173129&rft.pages=173129-173129&rft.artnum=173129&rft.issn=0091-3057&rft.eissn=1873-5177&rft_id=info:doi/10.1016/j.pbb.2021.173129&rft_dat=%3Cproquest_pubme%3E2483815780%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2483815780&rft_id=info:pmid/33515586&rft_els_id=S0091305721000277&rfr_iscdi=true